NCT07294118 Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage
| NCT ID | NCT07294118 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | The University of Texas Medical Branch, Galveston |
| Condition | Subarachnoid Hemorrhage, Aneurysmal |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2026-01-02 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 15 participants in total. It began in 2026-01-02 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if an infusion of lidocaine, with or without steroids, into the middle meningeal artery (MMA) helps relieve severe headaches in patients with spontaneous subarachnoid hemorrhage (SAH). It will also study the safety of this treatment.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years. * Diagnosed with aneurysmal SAH, Hunt and Hess Grades 1-2. * Consent to study procedures and follow-up evaluations. Exclusion Criteria: * Known allergies to lidocaine or steroids. * Arteriovenous malformations. * Dural Arteriovenous Fistulas. * Other significant intracranial pathologies. * Hemodynamic instability preventing safe intervention. * Previous MMA interventions. * Previous craniotomies or need for craniotomy. * Need for external ventricular drain.
Contact & Investigator
Kan Peter, MD
PRINCIPAL INVESTIGATOR
University of Texas Medical Branch, Galveston
Frequently Asked Questions
Who can join the NCT07294118 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Subarachnoid Hemorrhage, Aneurysmal. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07294118 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07294118 currently recruiting?
Yes, NCT07294118 is actively recruiting participants. Contact the research team at mlcosta@utmb.edu for enrollment information.
Where is the NCT07294118 trial being conducted?
This trial is being conducted at Galveston, United States.
Who is sponsoring the NCT07294118 clinical trial?
NCT07294118 is sponsored by The University of Texas Medical Branch, Galveston. The principal investigator is Kan Peter, MD at University of Texas Medical Branch, Galveston. The trial plans to enroll 15 participants.